title: Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity.
abstract: Metallothionein (MT) may provide protection against doxorubicin-induced heart damage. To test this hypothesis, a heart-specific promoter was used to drive the expression of human MT-IIa gene in transgenic mice. Four healthy transgenic mouse lines were produced. Cardiac MT was constitutively overexpressed from 10- to 130-fold higher than normal. The MT concentration was not altered in liver, kidneys, lungs, or skeletal muscles. Other antioxidant components including glutathione, glutathione peroxidase, glutathione reductase, catalase, and superoxide dismutase were not altered in the MT-overexpressing heart. Mice (7-wk-old) from transgenic lines expressing MT activity 10- or 130-fold higher than normal and from nontransgenic controls were treated intraperitoneally with doxorubicin at a single dose of 20 mg/kg, and were killed on the 4th day after treatment. As compared to normal controls, transgenic mice exhibited a significant resistance to in vivo doxorubicin-induced cardiac morphological changes, and the increase in serum creatine phosphokinase activity. Atria isolated from transgenic mice and treated with doxorubicin in tissue bath was also more resistant to functional damage induced by this drug. The results provide direct evidence for the role of MT in cardioprotection against doxorubicin toxicity.
authors.affiliation: Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky 40292, USA. ykang01@homer.louisville.edu
authors.forename: Y J
authors.initials: YJ
authors.lastname: Kang
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: A
authors.initials: A
authors.lastname: Yu
authors.forename: M
authors.initials: M
authors.lastname: Voss-McCowan
authors.forename: P N
authors.initials: PN
authors.lastname: Epstein
mesh_terms: D000818:Animals; D002374:Catalase / Q000378:metabolism; D003402:Creatine Kinase / Q000097:blood; D004317:Doxorubicin / Q000009:adverse effects*; D005260:Female; D005978:Glutathione / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D005980:Glutathione Reductase / Q000378:metabolism; D006331:Heart Diseases / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008668:Metallothionein / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008822:Mice, Transgenic; D008854:Microscopy, Electron; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000032:analysis; D013482:Superoxide Dismutase / Q000378:metabolism; D014018:Tissue Distribution
chemical_list: D012333:RNA, Messenger; D004317:Doxorubicin; D008668:Metallothionein; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005980:Glutathione Reductase; D003402:Creatine Kinase; D005978:Glutathione